Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 170 entries
Sorted by: Best Match Show Resources per page
Development and validation of a clinical risk score to predict mortality after percutaneous coronary intervention.

Open heart

Wall JJS, Iqbal J, Andrews M, Teare D, Ghobrial M, Hinton T, Turton S, Quffa L, El-Omar M, Fraser DG, Siotia A, Gunn J.
PMID: 28878944
Open Heart. 2017 Jul 25;4(2):e000576. doi: 10.1136/openhrt-2016-000576. eCollection 2017.

OBJECTIVE: To develop and validate a contemporary clinical risk score to predict mortality after percutaneous coronary intervention (PCI).METHODS: Using data collected from patients undergoing PCI at the South Yorkshire Cardiothoracic Centre, Sheffield, UK, between January 2007 and September 2013,...

Cite
Wall JJS, Iqbal J, Andrews M, et al. Development and validation of a clinical risk score to predict mortality after percutaneous coronary intervention. Open Heart. 2017;4(2):e000576doi: 10.1136/openhrt-2016-000576.
Wall, J. J. S., Iqbal, J., Andrews, M., Teare, D., Ghobrial, M., Hinton, T., Turton, S., Quffa, L., El-Omar, M., Fraser, D. G., Siotia, A., & Gunn, J. (2017). Development and validation of a clinical risk score to predict mortality after percutaneous coronary intervention. Open heart, 4(2), e000576. https://doi.org/10.1136/openhrt-2016-000576
Wall, Joshua J S, et al. "Development and validation of a clinical risk score to predict mortality after percutaneous coronary intervention." Open heart vol. 4,2 (2017): e000576. doi: https://doi.org/10.1136/openhrt-2016-000576
Wall JJS, Iqbal J, Andrews M, Teare D, Ghobrial M, Hinton T, Turton S, Quffa L, El-Omar M, Fraser DG, Siotia A, Gunn J. Development and validation of a clinical risk score to predict mortality after percutaneous coronary intervention. Open Heart. 2017 Jul 25;4(2):e000576. doi: 10.1136/openhrt-2016-000576. eCollection 2017. PMID: 28878944; PMCID: PMC5574428.
Copy Download .nbib Format: NLM
Autoimmune statin-induced myopathy: a case report.

Journal of community hospital internal medicine perspectives

Young JB, Ghobrial II.
PMID: 26333863
J Community Hosp Intern Med Perspect. 2015 Sep 01;5(4):28374. doi: 10.3402/jchimp.v5.28374. eCollection 2015.

A 58-year-old woman with a history of statin use presented with a 4-month history of progressive weakness of both shoulders and thighs. Laboratory and electromyography testing confirmed the presence of generalized proximal myopathy and ruled out connective tissue disease,...

Cite
Young JB, Ghobrial II. Autoimmune statin-induced myopathy: a case report. J Community Hosp Intern Med Perspect. 2015;5(4):28374doi: 10.3402/jchimp.v5.28374.
Young, J. B., & Ghobrial, I. I. (2015). Autoimmune statin-induced myopathy: a case report. Journal of community hospital internal medicine perspectives, 5(4), 28374. https://doi.org/10.3402/jchimp.v5.28374
Young, Jonathan B, and Ghobrial, Ibrahim I. "Autoimmune statin-induced myopathy: a case report." Journal of community hospital internal medicine perspectives vol. 5,4 (2015): 28374. doi: https://doi.org/10.3402/jchimp.v5.28374
Young JB, Ghobrial II. Autoimmune statin-induced myopathy: a case report. J Community Hosp Intern Med Perspect. 2015 Sep 01;5(4):28374. doi: 10.3402/jchimp.v5.28374. eCollection 2015. PMID: 26333863; PMCID: PMC4558286.
Copy Download .nbib Format: NLM
Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.

World journal of hepatology

Mukthinuthalapati PK, Gotur R, Ghabril M.
PMID: 27134701
World J Hepatol. 2016 Apr 28;8(12):533-44. doi: 10.4254/wjh.v8.i12.533.

Liver transplantation (LT) is associated with a 2 to 7 fold higher, age and gender adjusted, risk of de novo malignancy. The overall incidence of de novo malignancy post LT ranges from 2.2% to 26%, and 5 and 10...

Cite
Mukthinuthalapati PK, Gotur R, Ghabril M. Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World J Hepatol. 2016;8(12):533-44doi: 10.4254/wjh.v8.i12.533.
Mukthinuthalapati, P. K., Gotur, R., & Ghabril, M. (2016). Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World journal of hepatology, 8(12), 533-44. https://doi.org/10.4254/wjh.v8.i12.533
Mukthinuthalapati, Pavan Kedar, et al. "Incidence, risk factors and outcomes of de novo malignancies post liver transplantation." World journal of hepatology vol. 8,12 (2016): 533-44. doi: https://doi.org/10.4254/wjh.v8.i12.533
Mukthinuthalapati PK, Gotur R, Ghabril M. Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World J Hepatol. 2016 Apr 28;8(12):533-44. doi: 10.4254/wjh.v8.i12.533. PMID: 27134701; PMCID: PMC4840159.
Copy Download .nbib Format: NLM
The road to cure in multiple myeloma starts with smoldering disease.

Expert opinion on orphan drugs

Salem KZ, Ghobrial IM.
PMID: 25995973
Expert Opin Orphan Drugs. 2015 Apr 12;3(6). doi: 10.1517/21678707.2015.1036740.

INTRODUCTION: Smoldering multiple myeloma (SMM) is a heterogeneous clinical entity that defines patients in the spectrum of disease progression from monoclonal gammopathy of undetermined significance to multiple myeloma (MM). Current standard of care is observation until end organ damage...

Cite
Salem KZ, Ghobrial IM. The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs. 2015;3(6)doi: 10.1517/21678707.2015.1036740.
Salem, K. Z., & Ghobrial, I. M. (2015). The road to cure in multiple myeloma starts with smoldering disease. Expert opinion on orphan drugs, 3(6), . https://doi.org/10.1517/21678707.2015.1036740
Salem, Karma Z, and Ghobrial, Irene M. "The road to cure in multiple myeloma starts with smoldering disease." Expert opinion on orphan drugs vol. 3,6 (2015). doi: https://doi.org/10.1517/21678707.2015.1036740
Salem KZ, Ghobrial IM. The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs. 2015 Apr 12;3(6). doi: 10.1517/21678707.2015.1036740. PMID: 25995973; PMCID: PMC4435605.
Copy Download .nbib Format: NLM
Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

Ghobrial EE, El Hamshary AA, Mohamed AG, Abd El Raheim YA, Talaat AA.
PMID: 26022021
Saudi J Kidney Dis Transpl. 2015 May-Jun;26(3):507-15. doi: 10.4103/1319-2442.157350.

Systemic lupus erythematosus (SLE) is a life-long, life-limiting and multi-systemic autoimmune disease. Glomerulonephritis is one of the most serious manifestations of SLE. Younger children have an increased incidence, severity and morbidity of lupus nephritis (LN) compared with adult-onset disease....

Cite
Ghobrial EE, El Hamshary AA, Mohamed AG, et al. Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children. Saudi J Kidney Dis Transpl. 2015;26(3):507-15doi: 10.4103/1319-2442.157350.
Ghobrial, E. E., El Hamshary, A. A., Mohamed, A. G., Abd El Raheim, Y. A., & Talaat, A. A. (2015). Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 26(3), 507-15. https://doi.org/10.4103/1319-2442.157350
Ghobrial, Emad E, et al. "Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children." Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia vol. 26,3 (2015): 507-15. doi: https://doi.org/10.4103/1319-2442.157350
Ghobrial EE, El Hamshary AA, Mohamed AG, Abd El Raheim YA, Talaat AA. Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children. Saudi J Kidney Dis Transpl. 2015 May-Jun;26(3):507-15. doi: 10.4103/1319-2442.157350. PMID: 26022021.
Copy Download .nbib Format: NLM
Biological properties of extracellular vesicles and their physiological functions.

Journal of extracellular vesicles

Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O.
PMID: 25979354
J Extracell Vesicles. 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015.

In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and...

Cite
Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066doi: 10.3402/jev.v4.27066.
Yáñez-Mó, M., Siljander, P. R., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., Colás, E., Cordeiro-da Silva, A., Fais, S., Falcon-Perez, J. M., Ghobrial, I. M., Giebel, B., Gimona, M., Graner, M., Gursel, I., Gursel, M., Heegaard, N. H., Hendrix, A., Kierulf, P., Kokubun, K., Kosanovic, M., Kralj-Iglic, V., Krämer-Albers, E. M., Laitinen, S., Lässer, C., Lener, T., Ligeti, E., Linē, A., Lipps, G., Llorente, A., Lötvall, J., Manček-Keber, M., Marcilla, A., Mittelbrunn, M., Nazarenko, I., Nolte-'t Hoen, E. N., Nyman, T. A., O'Driscoll, L., Olivan, M., Oliveira, C., Pállinger, �. �., Del Portillo, H. A., Reventós, J., Rigau, M., Rohde, E., Sammar, M., Sánchez-Madrid, F., Santarém, N., Schallmoser, K., Ostenfeld, M. S., Stoorvogel, W., Stukelj, R., Van der Grein, S. G., Vasconcelos, M. H., Wauben, M. H., & De Wever, O. (2015). Biological properties of extracellular vesicles and their physiological functions. Journal of extracellular vesicles, 427066. https://doi.org/10.3402/jev.v4.27066
Yáñez-Mó, María, et al. "Biological properties of extracellular vesicles and their physiological functions." Journal of extracellular vesicles vol. 4 (2015): 27066. doi: https://doi.org/10.3402/jev.v4.27066
Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015. PMID: 25979354; PMCID: PMC4433489.
Copy Download .nbib Format: NLM
Mycophenolate mofetil: effects on clinical transplantation.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Holt CD, Sievers TM, Ghobrial RM, Rossi SJ, Goss JA, McDiarmid SV.
PMID: 18020609
BioDrugs. 1998 Nov;10(5):373-84. doi: 10.2165/00063030-199810050-00004.

Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic...

Cite
Holt CD, Sievers TM, Ghobrial RM, et al. Mycophenolate mofetil: effects on clinical transplantation. BioDrugs. 1998;10(5):373-84doi: 10.2165/00063030-199810050-00004.
Holt, C. D., Sievers, T. M., Ghobrial, R. M., Rossi, S. J., Goss, J. A., & McDiarmid, S. V. (1998). Mycophenolate mofetil: effects on clinical transplantation. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 10(5), 373-84. https://doi.org/10.2165/00063030-199810050-00004
Holt, C D, et al. "Mycophenolate mofetil: effects on clinical transplantation." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 10,5 (1998): 373-84. doi: https://doi.org/10.2165/00063030-199810050-00004
Holt CD, Sievers TM, Ghobrial RM, Rossi SJ, Goss JA, McDiarmid SV. Mycophenolate mofetil: effects on clinical transplantation. BioDrugs. 1998 Nov;10(5):373-84. doi: 10.2165/00063030-199810050-00004. PMID: 18020609.
Copy Download .nbib Format: NLM
A comparison of external and endoscopic endonasal dacryocystorhinostomy for acquired nasolacrimal duct obstruction.

Clinical ophthalmology (Auckland, N.Z.)

Karim R, Ghabrial R, Lynch T, Tang B.
PMID: 21792289
Clin Ophthalmol. 2011;5:979-89. doi: 10.2147/OPTH.S19455. Epub 2011 Jul 12.

PURPOSE: To compare success rates of external dacryocystorhinostomy (DCR) and endoscopic endonasal DCR for acquired nasolacrimal duct obstruction (NLDO).DESIGN: Historical cohort study.PARTICIPANTS: 100 patients who underwent external DCR and 105 patients who underwent endoscopic endonasal DCR.METHODS: A retrospective review...

Cite
Karim R, Ghabrial R, Lynch T, et al. A comparison of external and endoscopic endonasal dacryocystorhinostomy for acquired nasolacrimal duct obstruction. Clin Ophthalmol. 2011;5:979-89doi: 10.2147/OPTH.S19455.
Karim, R., Ghabrial, R., Lynch, T., & Tang, B. (2011). A comparison of external and endoscopic endonasal dacryocystorhinostomy for acquired nasolacrimal duct obstruction. Clinical ophthalmology (Auckland, N.Z.), 5979-89. https://doi.org/10.2147/OPTH.S19455
Karim, R, et al. "A comparison of external and endoscopic endonasal dacryocystorhinostomy for acquired nasolacrimal duct obstruction." Clinical ophthalmology (Auckland, N.Z.) vol. 5 (2011): 979-89. doi: https://doi.org/10.2147/OPTH.S19455
Karim R, Ghabrial R, Lynch T, Tang B. A comparison of external and endoscopic endonasal dacryocystorhinostomy for acquired nasolacrimal duct obstruction. Clin Ophthalmol. 2011;5:979-89. doi: 10.2147/OPTH.S19455. Epub 2011 Jul 12. PMID: 21792289; PMCID: PMC3141863.
Copy Download .nbib Format: NLM
Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance.

Journal of transplantation

Ghabril M, Dickson RC, Krishna M, Lloyd R, Aranda-Michel J, Keaveny A, Satyanarayana R, Bonatti H.
PMID: 20107579
J Transplant. 2009;2009:297528. doi: 10.1155/2009/297528. Epub 2009 May 05.

Background. Hepatitis C virus (HCV) nondetectability in the liver may predict a sustained viral response (SVR) in patients with an end of treatment response. HCV RNA can be detected in liver tissue by in situ hybridization (ISH). Aim. To...

Cite
Ghabril M, Dickson RC, Krishna M, et al. Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance. J Transplant. 2009;2009:297528doi: 10.1155/2009/297528.
Ghabril, M., Dickson, R. C., Krishna, M., Lloyd, R., Aranda-Michel, J., Keaveny, A., Satyanarayana, R., & Bonatti, H. (2009). Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance. Journal of transplantation, 2009297528. https://doi.org/10.1155/2009/297528
Ghabril, M, et al. "Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance." Journal of transplantation vol. 2009 (2009): 297528. doi: https://doi.org/10.1155/2009/297528
Ghabril M, Dickson RC, Krishna M, Lloyd R, Aranda-Michel J, Keaveny A, Satyanarayana R, Bonatti H. Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance. J Transplant. 2009;2009:297528. doi: 10.1155/2009/297528. Epub 2009 May 05. PMID: 20107579; PMCID: PMC2809420.
Copy Download .nbib Format: NLM
Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury: Functional Outcomes at 12 Months in a Phase II Clinical Trial.

Neurosurgery

Ghobrial GM, Anderson KD, Dididze M, Martinez-Barrizonte J, Sunn GH, Gant KL, Levi AD.
PMID: 28899046
Neurosurgery. 2017 Sep 01;64:87-91. doi: 10.1093/neuros/nyx242.

No abstract available.

Cite
Ghobrial GM, Anderson KD, Dididze M, et al. Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury: Functional Outcomes at 12 Months in a Phase II Clinical Trial. Neurosurgery. 2017;64:87-91doi: 10.1093/neuros/nyx242.
Ghobrial, G. M., Anderson, K. D., Dididze, M., Martinez-Barrizonte, J., Sunn, G. H., Gant, K. L., & Levi, A. D. (2017). Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury: Functional Outcomes at 12 Months in a Phase II Clinical Trial. Neurosurgery, 6487-91. https://doi.org/10.1093/neuros/nyx242
Ghobrial, George M, et al. "Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury: Functional Outcomes at 12 Months in a Phase II Clinical Trial." Neurosurgery vol. 64 (2017): 87-91. doi: https://doi.org/10.1093/neuros/nyx242
Ghobrial GM, Anderson KD, Dididze M, Martinez-Barrizonte J, Sunn GH, Gant KL, Levi AD. Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury: Functional Outcomes at 12 Months in a Phase II Clinical Trial. Neurosurgery. 2017 Sep 01;64:87-91. doi: 10.1093/neuros/nyx242. PMID: 28899046.
Copy Download .nbib Format: NLM
Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement.

Polish journal of radiology

Ghobrial FEI, Eldin MS, Razek AAKA, Atwan NI, Shamaa SSA.
PMID: 29657622
Pol J Radiol. 2017 Oct 20;82:593-597. doi: 10.12659/PJR.902930. eCollection 2017.

BACKGROUND: To assess inter-observer agreement of revised RECIST criteria (version 1.1) for computed tomography assessment of hepatic metastases of breast cancer.MATERIAL/METHODS: A prospective study was conducted in 28 female patients with breast cancer and with at least one measurable...

Cite
Ghobrial FEI, Eldin MS, Razek AAKA, et al. Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement. Pol J Radiol. 2017;82:593-597doi: 10.12659/PJR.902930.
Ghobrial, F. E. I., Eldin, M. S., Razek, A. A. K. A., Atwan, N. I., & Shamaa, S. S. A. (2017). Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement. Polish journal of radiology, 82593-597. https://doi.org/10.12659/PJR.902930
Ghobrial, Fady Emil Ibrahim, et al. "Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement." Polish journal of radiology vol. 82 (2017): 593-597. doi: https://doi.org/10.12659/PJR.902930
Ghobrial FEI, Eldin MS, Razek AAKA, Atwan NI, Shamaa SSA. Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement. Pol J Radiol. 2017 Oct 20;82:593-597. doi: 10.12659/PJR.902930. eCollection 2017. PMID: 29657622; PMCID: PMC5894063.
Copy Download .nbib Format: NLM
Anion Inhibition Profile of the β-Carbonic Anhydrase from the Opportunist Pathogenic Fungus .

Metabolites

Prete SD, Angeli A, Ghobril C, Hitce J, Clavaud C, Marat X, Supuran CT, Capasso C.
PMID: 31323880
Metabolites. 2019 Jul 18;9(7). doi: 10.3390/metabo9070147.

Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes, which catalyze the crucial physiological CO

Cite
Prete SD, Angeli A, Ghobril C, et al. Anion Inhibition Profile of the β-Carbonic Anhydrase from the Opportunist Pathogenic Fungus . Metabolites. 2019;9(7)doi: 10.3390/metabo9070147.
Prete, S. D., Angeli, A., Ghobril, C., Hitce, J., Clavaud, C., Marat, X., Supuran, C. T., & Capasso, C. (2019). Anion Inhibition Profile of the β-Carbonic Anhydrase from the Opportunist Pathogenic Fungus . Metabolites, 9(7), . https://doi.org/10.3390/metabo9070147
Prete, Sonia Del, et al. "Anion Inhibition Profile of the β-Carbonic Anhydrase from the Opportunist Pathogenic Fungus ." Metabolites vol. 9,7 (2019). doi: https://doi.org/10.3390/metabo9070147
Prete SD, Angeli A, Ghobril C, Hitce J, Clavaud C, Marat X, Supuran CT, Capasso C. Anion Inhibition Profile of the β-Carbonic Anhydrase from the Opportunist Pathogenic Fungus . Metabolites. 2019 Jul 18;9(7). doi: 10.3390/metabo9070147. PMID: 31323880; PMCID: PMC6680850.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 170 entries